VG Med WF 136598c lungs bronchi traction bronchiectasis subpleural sparing volume loss lower lung fields esophagus air fluid level Fibrotic NSIP CT lungs bronchi traction bronchiectasis subpleural sparing volume loss lower lung fields esophagus air fluid level Fibrotic NSIP CT 59M pw Hx history of scleroderma ILD
<
<
Traction Bronchiectasis
1. Challenge
Ashley Davidoff MD
59M pw Hx history of scleroderma ILD
Fibrotic NSIP 59-year-old male presents with history of scleroderma, Raynaud’s disease, and ILD Upper Image Axial CT shows bronchiectasis, and bronchiolectasis with crowding of the bronchovascular bundles posteriorly, with volume loss (note fissural displacement -pink arrowheads). There is subpleural sparing posteriorly. Minor changes of peripheral reticular changes and minimal ground glass changes are present. An air-fluid level is present in the distended esophagus indicating reflux. The lower image focuses on the traction bronchiectasis caused by the fibrotic process Ashley Davidoff MD TheCommonVein.net 110Lu 136598c
Traction Bronchiectasis Subpleural Sparing Volume Loss Lower Lung Fields Esophagus Air Fluid Level
Fibrotic NSIP 59-year-old male presents with history of scleroderma, Raynaud’s disease, and ILD Upper Image Axial CT shows bronchiectasis, and bronchiolectasis with crowding of the bronchovascular bundles posteriorly (green arrowheads) with volume loss (note fissural displacement -pink arrowheads). There is subpleural sparing posteriorly (blue arrowheads) Minor changes of peripheral reticular changes (black arrowheads), and minimal ground glass changes are present. An air-fluid level is present in the distended esophagus indicating reflux (yellow arrowhead). The lower image focuses on the traction bronchiectasis caused by the fibrotic process Ashley Davidoff MD TheCommonVein.net 110Lu 136598cL
Finding
Definition
Comment
Traction Bronchiectasis and Bronchiolectasis
Irreversible and irregular bronchial and bronchiolar dilatation caused by the pulling force of surrounding pulmonary fibrosis.
This finding is a key feature of fibrotic lung disease. In the context of scleroderma, it is commonly seen in the fibrotic non-specific interstitial pneumonia (NSIP) pattern. The fibrotic process distorts the airways, leading to their widening.
Goldin JG, J Comput Assist Tomogr, 2008
Subpleural Sparing
A CT imaging finding where pathology affecting the lungs spares the peripheral lung margin adjacent to the pleura.
This is considered a characteristic feature of non-specific interstitial pneumonia (NSIP) and helps differentiate it from usual interstitial pneumonia (UIP), which typically involves the subpleural regions. The underlying mechanism may be related to the robust lymphatic drainage in the immediate subpleural zone.
Travis WD, Am J Surg Pathol, 2000
Volume Loss in Lower Lung Fields
A reduction in the volume of the lower lobes of the lungs, often a consequence of progressive pulmonary fibrosis.
In fibrotic NSIP, volume loss is typically observed in the lower lobes and is associated with traction bronchiectasis. This restrictive pattern of lung disease is a common physiological consequence of interstitial lung diseases like the one seen in scleroderma.
Tashkin DP, Chest, 2021
Esophagus Air-Fluid Level
The presence of both air and fluid in a dilated esophagus, visible on CT imaging.
Esophageal dysmotility and dilation are very common in patients with scleroderma, occurring in up to 80-90% of cases. The atrophy of smooth muscle leads to a flaccid, dilated esophagus, which can result in the retention of fluid and air, often detectable on chest CT even in asymptomatic patients. An esophageal diameter greater than 10-15mm on CT is considered dilated and is highly suggestive of esophageal involvement in scleroderma.
Fibrotic NSIP 59-year-old male presents with history of scleroderma, Raynaud’s disease, and ILD CXR shows basilar reticular changes and low lung volumes. There is an air bronchogram in the left lower lobe as a result of traction bronchiectasis and fibrotic change surrounding the bronchovascular bundle The CT highlights the bronchovascular thickening, and bronchiectasis that results in the air bronchogram. In addition there is volume loss, and subpleural sparing. The fibrotic process has resulted in traction of the secondary lobules in the region of subpleural sparing Ashley Davidoff MD TheCommonVein.net 110Lu 136592c
This clinical perspective will focus on traction bronchiectasis and bronchiolectasis, using Fibrotic Nonspecific Interstitial Pneumonia (fNSIP) as a primary example while also discussing other conditions where these findings are prevalent.
Traction Bronchiectasis
Definition
Traction bronchiectasis and the more peripheral traction bronchiolectasis are defined as the abnormal and irreversible dilation of the bronchi and bronchioles, respectively. This is not a primary airway disease but rather a direct consequence of surrounding lung disease.
This process occurs when established pulmonary fibrosis exerts a pulling force (traction) on the airway walls, causing them to stretch and widen.
These findings are considered definitive signs of fibrosis on high-resolution computed tomography (HRCT) and are key features in many interstitial lung diseases (ILDs), including fNSIP and usual interstitial pneumonia (UIP).
Cause & Associated Conditions
The underlying cause of traction bronchiectasis and bronchiolectasis is always pulmonary fibrosis.
Any disease process that leads to significant lung scarring can cause this finding. Common examples include:
Fibrotic Nonspecific Interstitial Pneumonia (fNSIP): Often associated with connective tissue diseases like scleroderma, fNSIP typically shows traction bronchiectasis within areas of ground-glass opacity and fine reticulation.
Usual Interstitial Pneumonia (UIP): The pattern seen in Idiopathic Pulmonary Fibrosis (IPF) and some connective tissue diseases, where traction bronchiectasis is a required feature, often alongside honeycombing.
Chronic Hypersensitivity Pneumonitis (cHP): Fibrosis in cHP can lead to traction bronchiectasis, often with a mid- to upper-lung predominance.
End-stage Sarcoidosis: As granulomatous inflammation is replaced by fibrosis, significant traction bronchiectasis develops, typically in the upper lobes.
Other causes: Radiation-induced lung fibrosis and asbestosis are other notable causes.
Pathophysiology
The process begins with injury to the lung parenchyma, triggering an inflammatory and subsequent fibrotic response.
Key profibrotic mediators, most notably Transforming Growth Factor-beta (TGF-β), stimulate fibroblasts to transform into myofibroblasts.
These activated myofibroblasts excessively deposit extracellular matrix (e.g., collagen), leading to the formation of dense scar tissue.
As this scar tissue matures and contracts, it exerts a mechanical pulling force on the walls of the adjacent bronchi and bronchioles.
Since these airways are tethered within the stiffening lung parenchyma, they are pulled open, resulting in permanent, irregular dilation, which is termed traction bronchiectasis and bronchiolectasis.
Structural Result
Irreversible and uneven dilation of the airways (bronchi and bronchioles) within the areas of fibrosis.
The lung architecture becomes distorted, and there is an overall loss of lung volume as the fibrotic tissue contracts.
Unlike primary forms of bronchiectasis, the airway wall itself is not the primary site of disease; rather, it is a victim of the surrounding parenchymal process.
Functional Impact
The underlying fibrosis, which causes traction bronchiectasis, leads to a restrictive ventilatory defect on Pulmonary Function Tests (PFTs), characterized by a reduction in Forced Vital Capacity (FVC) and Total Lung Capacity (TLC).
Gas exchange is impaired due to the thickened and scarred interstitium, resulting in a reduced Diffusing Capacity of the Lung for Carbon Monoxide (DLCO).
Clinically, patients experience progressive shortness of breath on exertion and often a dry, non-productive cough.
Imaging
High-Resolution Computed Tomography (HRCT) is the imaging standard for identifying traction bronchiectasis and bronchiolectasis.
On HRCT, they appear as dilated airways that do not taper normally toward the periphery and are often visible within 1 cm of the pleural surface. Their shape is typically irregular, varicose, or cystic.
The key diagnostic feature is their location: they are always embedded within other signs of fibrosis, such as reticulation, ground-glass opacities, or honeycombing.
In fNSIP, they are often seen within areas of ground-glass opacity with associated reticulation and subpleural sparing. In UIP, they are typically found within areas of coarse reticulation and honeycombing in a subpleural and basal distribution.
Treatment
There is no treatment to reverse established traction bronchiectasis, as it represents permanent scarring.
Therapy is directed at the underlying fibrotic lung disease.
For inflammatory-driven fibrosis (like in some cases of fNSIP or cHP), immunosuppressants such as mycophenolate mofetil or azathioprine may be used.
For progressive fibrotic phenotypes (including IPF and progressive SSc-ILD), antifibrotic medications like nintedanib or pirfenidone are used to slow the rate of lung function decline.
Supportive care, including supplemental oxygen, pulmonary rehabilitation, and vaccinations, is a crucial part of management.
Prognosis
The presence and severity of traction bronchiectasis and bronchiolectasis are powerful predictors of worse outcomes.
Studies have consistently shown that an increased extent of traction bronchiectasis on HRCT is strongly associated with a more rapid decline in lung function and increased all-cause mortality in various ILDs, including IPF and interstitial lung abnormalities (ILA).
Even the presence of subtle traction bronchiolectasis, without obvious bronchiectasis, can be an early sign of fibrosis and is associated with shorter survival.
Therefore, identifying and quantifying the extent of traction bronchiectasis is critical for risk stratification and prognostic assessment in patients with fibrotic lung disease.
Traction Bronchiectasis and Bronchiolectasis: “Bronchiectasis” is from the Greek bronkhia (airway) + ektasis (stretching). “Bronchiolectasis” follows the same root for the smaller bronchioles. The term “traction” specifies that this stretching is caused by the pulling forces of adjacent scar tissue (fibrosis), a key feature in fibrotic ILD. Traction bronchiectasis involves larger airways (bronchi), while traction bronchiolectasis involves the smaller, more peripheral airways (bronchioles). Both are considered definitive signs of fibrosis.
AKA / Terminology
N/A
Historical Notes
1819: René Laennec first discovered bronchiectasis using his invention, the stethoscope.
1986: The term traction bronchiectasis was described in the context of end-stage pulmonary fibrosis, noting it as a direct result of the fibrotic process rather than primary bronchial disease. As HRCT resolution improved, this concept was extended to the smaller airways, termed traction bronchiolectasis.
1994: The term “nonspecific interstitial pneumonia/fibrosis” was formally introduced by pathologists Anna-Luise Katzenstein and Robert Fiorelli. The ability to radiologically identify fibrosis through signs like traction bronchiectasis and bronchiolectasis became crucial in correlating pathology with imaging.
2008 & 2013: Subsequent ATS/ERS updates solidified idiopathic NSIP as a distinct clinical entity, heavily relying on HRCT patterns where traction bronchiectasis and bronchiolectasis serve as definitive signs of the fibrotic component.
Cultural or Practice Insights
Prognostic Shift: The ability to distinguish NSIP from UIP, often based on the pattern of fibrosis and the presence or absence of honeycombing alongside traction bronchiectasis and bronchiolectasis, was a significant advance in prognostication.
Diagnostic Approach: For radiologists, identifying traction bronchiectasis and traction bronchiolectasis on HRCT is a critical diagnostic clue, as it serves as an unequivocal sign of underlying fibrosis. Its presence helps steer the diagnosis towards a fibrotic process like fNSIP or UIP.
World Scleroderma Day: June 29th is designated as World Scleroderma Day.
Notable Figures or Contributions
Anna-Luise Katzenstein and Robert F. Fiorelli: The pathologists who first described NSIP. Their work laid the foundation for radiologists to later identify the imaging correlates, such as ground glass, reticulation, and traction bronchiectasis and bronchiolectasis.
William Osler: Provided comprehensive early descriptions of the visceral manifestations of scleroderma. The pulmonary component he described is now understood as the fibrosis that leads to traction bronchiectasis and bronchiolectasis.
Painting
Paul Klee (1879-1940): His later work was profoundly influenced by scleroderma. The physical limitations and shortness of breath he experienced are directly related to the lung fibrosis and traction bronchiectasis and bronchiolectasis seen in SSc-ILD.
Sculpture
Themes of confinement and the struggle for breath seen in works like Michelangelo’s ‘Dying Slave’ can be metaphorically linked to the experience of progressive fibrotic lung disease, where the airways are distorted by traction bronchiectasis and bronchiolectasis.
Photography
Contemporary medical imaging, particularly HRCT, can be seen as a form of photography that makes the internal struggle visible. Images clearly depicting traction bronchiectasis and bronchiolectasis offer a stark, objective portrait of the disease’s impact on the lungs.
Literature
The subgenre of “sick lit” explores the challenges of chronic illness. The physical constraint described in these works mirrors the physiological constraint of the lungs by fibrosis and traction bronchiectasis and bronchiolectasis.
Poetry
The themes often revolve around breath, constraint, and the body’s transformation.
From skleros, the hardening begins, A collagen shroud on yielding skins. Then whispers turn to shallow sighs, As deep within, the lung-field tries To draw the world, a breath profound, But finds itself in fibrous ground. The bronchi stretch, the bronchioles too, In traction’s unrelenting pull. A lower lobe, no longer full. Subpleural sparing, glass obscured, A future slowly reconfigured.
Quotes and/or Teaching Lines
“Where you see traction bronchiectasis and bronchiolectasis, you see fibrosis. It’s the lung’s testament to the scarring that has taken place.”
“Traction bronchiectasis is the radiological sign that separates reversible inflammation from irreversible fibrosis.”
“Traction bronchiectasis is the pull on the larger airways; traction bronchiolectasis is the same fibrotic grip on the delicate, peripheral bronchioles. Both scream fibrosis.”
Regarding NSIP’s classification: Initially a “wastebasket” category, its recognition as an entity relies on specific patterns where the presence and distribution of traction bronchiectasis and bronchiolectasis are key differentiators.
1. Basic Science: What is the fundamental pathomechanical process that causes traction bronchiectasis?
A. Chronic airway infection leading to bronchial wall destruction and mucus plugging. B. Congenital weakness in the bronchial cartilage leading to airway collapse and subsequent dilation. C. Outward pulling forces from surrounding parenchymal fibrosis that distort and irreversibly dilate the airways. D. Infiltration of the bronchial walls by inflammatory cells, causing direct weakening and widening.
2. Basic Science: The development of fibrosis, which is the underlying cause of traction bronchiectasis, is primarily driven by the activation of fibroblasts into myofibroblasts. Which cytokine is the most potent and direct mediator of this transformation?
A. Interleukin-1 (IL-1) B. Tumor Necrosis Factor-alpha (TNF-α) C. Interferon-gamma (IFN-γ) D. Transforming Growth Factor-beta (TGF-β)
3. Clinical: The presence and extent of traction bronchiectasis on HRCT in a patient with a known fibrotic interstitial lung disease (like fNSIP or IPF) is a significant prognostic indicator. It is most strongly associated with:
A. A favorable response to immunosuppressive therapy. B. A higher likelihood of spontaneous disease remission. C. Increased severity of fibrosis and higher mortality. D. A lower risk of developing pulmonary hypertension.
4. Clinical: While traction bronchiectasis is a hallmark of fibrotic lung disease, in which of the following conditions is it LEAST likely to be a dominant feature?
A. Usual Interstitial Pneumonia (UIP) B. Cellular Nonspecific Interstitial Pneumonia (cNSIP) <input_type=”checkbox”> C. Chronic Hypersensitivity Pneumonitis (cHP) <input_type=”checkbox”> D. End-stage Sarcoidosis
5. Imaging: In differentiating fNSIP from UIP, the pattern of traction bronchiectasis can be a clue. Which description best fits the typical appearance of traction bronchiectasis in fNSIP?
A. Primarily associated with extensive honeycombing in a basal and subpleural distribution. B. Uniformly cylindrical, involving only the central cartilaginous airways. C. Associated with ground-glass opacities and reticulation, often with relative subpleural sparing. D. Almost exclusively seen in the upper lobes with associated large bullae.
6. Imaging: Besides fNSIP and UIP, traction bronchiectasis is a key feature in other fibrotic lung diseases. In which of the following diseases is it classically associated with a mid- or upper-lung zone predominance and possibly centrilobular nodules?
A. Asbestosis B. Rheumatoid Arthritis-associated ILD (UIP pattern) C. Chronic Hypersensitivity Pneumonitis (cHP) D. Drug-induced lung injury (Amiodarone)
7. Imaging: On HRCT, how is traction bronchiectasis definitively differentiated from other forms of bronchiectasis, such as post-infectious bronchiectasis?
A. Traction bronchiectasis always shows a “signet ring” sign, while post-infectious does not. B. Traction bronchiectasis occurs within and is caused by surrounding parenchymal fibrosis, whereas post-infectious bronchiectasis is a primary airway disease that may or may not have adjacent fibrosis. C. Post-infectious bronchiectasis is always reversible, while traction bronchiectasis is permanent. D. Traction bronchiectasis exclusively affects the lower lobes, whereas post-infectious bronchiectasis affects the upper lobes.
Part B
1. What is the fundamental pathomechanical process that causes traction bronchiectasis?
A. Chronic airway infection leading to bronchial wall destruction and mucus plugging.
❌
Incorrect. This describes the “vicious cycle” hypothesis for other forms of bronchiectasis, such as post-infectious or cystic fibrosis-related, not traction bronchiectasis.
B. Congenital weakness in the bronchial cartilage leading to airway collapse and subsequent dilation.
❌
Incorrect. This describes the mechanism for conditions like Williams-Campbell syndrome, which is a rare congenital cause of bronchiectasis, not traction bronchiectasis.
C. Outward pulling forces from surrounding parenchymal fibrosis that distort and irreversibly dilate the airways.
✅
Correct. Traction bronchiectasis is, by definition, the result of mechanical pulling (traction) from scarred and fibrotic lung tissue surrounding the bronchi, causing them to widen irreversibly.
Westcott JL, Cole SR. Radiology. 1986
D. Infiltration of the bronchial walls by inflammatory cells, causing direct weakening and widening.
❌
Incorrect. While inflammation is part of the overall disease process in ILDs, the specific mechanism of traction bronchiectasis is the mechanical pulling by established fibrosis, not direct inflammation of the airway wall itself.
2. The development of fibrosis, which is the underlying cause of traction bronchiectasis, is primarily driven by the activation of fibroblasts into myofibroblasts. Which cytokine is the most potent and direct mediator of this transformation?
A. Interleukin-1 (IL-1)
❌
Incorrect. IL-1 is a pro-inflammatory cytokine but is not considered the principal direct driver of fibroblast-to-myofibroblast transformation.
B. Tumor Necrosis Factor-alpha (TNF-α)
❌
Incorrect. Like IL-1, TNF-α is a key inflammatory mediator but is not the primary profibrotic cytokine responsible for myofibroblast activation.
C. Interferon-gamma (IFN-γ)
❌
Incorrect. IFN-γ is generally considered to have anti-fibrotic properties, acting to inhibit collagen synthesis.
D. Transforming Growth Factor-beta (TGF-β)
✅
Correct. TGF-β is the most well-established and potent cytokine that promotes fibrosis by inducing the differentiation of fibroblasts into collagen-producing myofibroblasts, leading to the scar tissue that causes traction bronchiectasis.
Khalil N, et al. Am J Respir Cell Mol Biol. 2020
3. The presence and extent of traction bronchiectasis on HRCT in a patient with a known fibrotic interstitial lung disease (like fNSIP or IPF) is a significant prognostic indicator. It is most strongly associated with:
A. A favorable response to immunosuppressive therapy.
❌
Incorrect. Traction bronchiectasis indicates irreversible fibrosis, which is generally less responsive to therapy than active inflammation (often seen as ground-glass opacity).
B. A higher likelihood of spontaneous disease remission.
❌
Incorrect. Traction bronchiectasis is a sign of established, often progressive fibrosis, not a disease process likely to remit spontaneously.
C. Increased severity of fibrosis and higher mortality.
✅
Correct. Multiple studies have shown that the presence and severity of traction bronchiectasis are powerful radiologic markers that correlate with the severity of fibrosis, progressive decline in lung function, and increased mortality across different types of fibrotic ILD.
Hida T, et al. Eur J Radiol Open. 2021
D. A lower risk of developing pulmonary hypertension.
❌
Incorrect. Severe fibrosis, of which traction bronchiectasis is a sign, often leads to destruction of the pulmonary vascular bed, which can cause or worsen pulmonary hypertension (Group 3 PH), thus indicating a higher, not lower, risk.
4. While traction bronchiectasis is a hallmark of fibrotic lung disease, in which of the following conditions is it LEAST likely to be a dominant feature?
A. Usual Interstitial Pneumonia (UIP)
❌
Incorrect. Traction bronchiectasis is a key and required feature for a definite UIP pattern on HRCT.
B. Cellular Nonspecific Interstitial Pneumonia (cNSIP)
✅
Correct. The cellular subtype of NSIP is defined pathologically by interstitial inflammation with minimal to no fibrosis. Therefore, traction bronchiectasis, which is caused by fibrosis, is characteristically absent or minimal.
Travis WD, et al. Am J Respir Crit Care Med. 2002
C. Chronic Hypersensitivity Pneumonitis (cHP)
❌
Incorrect. The fibrotic form of chronic HP is characterized by fibrosis and architectural distortion, which includes traction bronchiectasis.
D. End-stage Sarcoidosis
❌
Incorrect. As sarcoidosis progresses to its fibrotic, end-stage form, it causes significant parenchymal scarring and architectural distortion, which commonly results in traction bronchiectasis, often with an upper-lobe predominance.
5. In differentiating fNSIP from UIP, the pattern of traction bronchiectasis can be a clue. Which description best fits the typical appearance of traction bronchiectasis in fNSIP?
A. Primarily associated with extensive honeycombing in a basal and subpleural distribution.
❌
Incorrect. This description is the hallmark of a definite UIP pattern. Honeycombing is characteristically absent or minimal in NSIP.
B. Uniformly cylindrical, involving only the central cartilaginous airways.
❌
Incorrect. Traction bronchiectasis typically affects peripheral airways within areas of fibrosis and is irregular, not uniform or limited to central airways.
C. Associated with ground-glass opacities and reticulation, often with relative subpleural sparing.
✅
Correct. The typical fibrotic NSIP pattern consists of ground-glass opacities and fine reticulation with associated traction bronchiectasis. A key distinguishing feature from UIP is the relative sparing of the immediate subpleural lung.
Silva CI, et al. Radiographics. 2008
D. Almost exclusively seen in the upper lobes with associated large bullae.
❌
Incorrect. This describes a pattern more consistent with advanced smoking-related lung disease or fibrotic sarcoidosis, not the typical basal predominance of fNSIP.
6. Besides fNSIP and UIP, traction bronchiectasis is a key feature in other fibrotic lung diseases. In which of the following diseases is it classically associated with a mid- or upper-lung zone predominance and possibly centrilobular nodules?
A. Asbestosis
❌
Incorrect. Asbestosis typically causes a basilar and subpleural predominant fibrosis, similar in distribution to UIP.
B. Rheumatoid Arthritis-associated ILD (UIP pattern)
❌
Incorrect. When RA-ILD presents with a UIP pattern, it has the same basal and peripheral predominance as idiopathic UIP.
C. Chronic Hypersensitivity Pneumonitis (cHP)
✅
Correct. Chronic HP often presents with fibrosis (including traction bronchiectasis) in a mid- or upper-lung zone distribution. The presence of poorly defined centrilobular nodules and air trapping (mosaic attenuation) are also key features that suggest cHP.
Silva CIS, et al. RadioGraphics. 2007
D. Drug-induced lung injury (Amiodarone)
❌
Incorrect. While amiodarone can cause fibrotic lung disease, its classic presentation often involves high-attenuation opacities due to the iodine content of the drug, and the distribution is not classically mid- to upper-zonal.
7. On HRCT, how is traction bronchiectasis definitively differentiated from other forms of bronchiectasis, such as post-infectious bronchiectasis?
A. Traction bronchiectasis always shows a “signet ring” sign, while post-infectious does not.
❌
Incorrect. The “signet ring” sign (bronchus diameter greater than the adjacent pulmonary artery) can be seen in various types of bronchiectasis, not just traction type.
B. Traction bronchiectasis occurs within and is caused by surrounding parenchymal fibrosis, whereas post-infectious bronchiectasis is a primary airway disease that may or may not have adjacent fibrosis.
✅
Correct. This is the core distinction. The key diagnostic feature of traction bronchiectasis is that the dilated airways are situated within an area of clear parenchymal pathology (fibrosis, reticulation, architectural distortion). Other forms of bronchiectasis are primary airway pathologies.
Hansell DM, et al. Radiology. 2008
C. Post-infectious bronchiectasis is always reversible, while traction bronchiectasis is permanent.
❌
Incorrect. Both conditions represent permanent, irreversible airway dilation. While some *pseudo*bronchiectasis after acute inflammation can be reversible, established bronchiectasis of any primary cause is not.
D. Traction bronchiectasis exclusively affects the lower lobes, whereas post-infectious bronchiectasis affects the upper lobes.
❌
Incorrect. The distribution of traction bronchiectasis depends entirely on the location of the underlying fibrosis (e.g., basal in UIP/NSIP, upper lobes in sarcoidosis). Post-infectious bronchiectasis can also occur in any lobe.
Artistic Rendering of Traction Bronchiectasis Modified AI image by Ashley Davidoff MD, TheCommonVein.com (140536.MAD. lungs-bronchi-traction-bronchiectasis) Traction Bronchiectasis: A Tug-of-War of Fibrosis
This AI-assisted memory image is a metaphorical collage illustrating the mechanism of Traction Bronchiectasis, a common finding in advanced interstitial lung disease. The image uses a tug-of-war theme where men pull thick ropes on a tracheobronchial “tree,” symbolizing the external traction exerted by dense scar tissue (fibrosis). The central CT image shows the result: permanently dilated bronchi mimicking the stretched rope segments, with the jungle background representing the disordered and scarred interstitial architecture of fibrotic NSIP (Nonspecific Interstitial Pneumonia).The metaphor vividly explains that traction bronchiectasis is caused by the stiffening and contraction of the surrounding lung tissue, which mechanically pulls the bronchial walls open, differentiating it from forms caused by muscle wall destruction or obstruction. Modified AI image by Ashley Davidoff Art, TheCommonVein.com (140536.MAD-04.lungs-bronchi-traction-bronchiectasis)
The Fibrotic Tug on the Tree
The lung’s soft landscape, once green and free, Is now a jungle, a tangled, dense tree. The NSIP whispers, a fibrous slow hand, Stiffening pliable tissue and distorted large bands .
See the CT’s small windows, a central clear view, Where the airways are widened, pathologically new. They stretch and they gape, they cannot retract, For the pull of the scar tissue holds them fast, exact.
Like men in the collage, with ropes thick and taut, The collagen fibers the bronchi have caught. They pull with a force, a silent, slow fight, Exerting their traction with desperate might.
The tracheobronchial tree, once a conduit of air, Is locked in a struggle, a permanent snare. This widening, lasting, this structural breach, Is Traction Bronchiectasis, a lesson they teach. The jungle of fibrosis has won its grim prize, Reflected in tubes with unblinking eyes.
1819: 
